The team remains hard at work on the multiple pre-clinical projects that are underway, all due to be completed later this year. The results of these critical translational studies will form the basis of the IND application that will be submitted to the FDA in order to commence clinical trials. While it seems that there is never a “dull moment” during an undertaking of this scope, things are basically going as planned. In March we visited our funding agency, CIRM, to present our plans for product development. We also hosted a meeting in which our manufacturing process was reviewed in preparation for the IND application. In April I presented our work at the World Ophthalmology Congress in Tokyo and at the PLA Hospital in Beijing. Our team skipped the annual ARVO conference this year for the first time in a long while, in order to stay focused on the urgent job at hand, although I presented our work at the session on Cell Therapy in Ocular Disease, held prior to the main meeting. Next month I will be presenting at ISOPT Clinical in Reykjavik, in case anyone wants to swing by for some artic char and a listen.
May 2014 Update from Dr. Henry Klassen
Posted in News